Report : Asia Pacific Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly People) 

At 6.9% CAGR, the Asia Pacific Influenza Vaccines Market is speculated to be worth US$ 2,669.27 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific influenza vaccines market was valued at US$ 1,688.07 million in 2022 and is expected to reach US$ 2,669.27 million by 2028, registering a CAGR of 6.9% from 2022 to 2028. Increase in government support to promote influenza vaccination and increasing investment by top market players and governments are the critical factors attributed to the market expansion.

Market players and governments worldwide are increasing their investments in vaccine development and immunization. In November 2020, Vaccine maker Seqirus planned to invest US$ 800 million in a significant Australian vaccine manufacturing center. The new plant will be located at Tullamarine in the business district of Melbourne Airport and is expected to come online in 2026, Seqirus said. The company did not disclose the desired square meter area in a statement. In March 2022, The Australian Government announced a US$ 100 million investment in a seasonal flu vaccine. The objective of this investment is to protect people from influenza and COVID-19 to minimize its impact on healthcare in Australia. Thus, the increase in investment by top market players and governments across the region is bolstering the Asia Pacific influenza vaccines market.

On the contrary, high cost of vaccine development hampers the Asia Pacific influenza vaccines market. 

Based on vaccine type, the Asia Pacific influenza vaccines market is segmented into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment held 89.3% market share in 2022, amassing US$ 1,507.34 million. It is projected to garner US$ 2,420.49 million by 2028 to expand at 8.2% CAGR during 2022–2028.

Based on virus type, the Asia Pacific influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held 95.1% market share in 2022, amassing US$ 1,605.64 million. It is projected to garner US$ 2,566.94 million by 2028 to expand at 8.1% CAGR during 2022–2028.

Based on technology, the Asia Pacific influenza vaccines market is segmented into egg-based and cell-based. The egg-based segment held 78.8% market share in 2022, amassing US$ 1,330.61 million. It is projected to garner US$ 2,072.38 million by 2028 to expand at 7.7% CAGR during 2022–2028.

Based on route of administration, the Asia Pacific influenza vaccines market is segmented into injection and nasal spray. The injection segment held 73.7% market share in 2022, amassing US$ 1,243.40 million. It is projected to garner US$ 2,004.86 million by 2028 to expand at 8.3% CAGR during 2022–2028.

Based on target group, the Asia Pacific influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held 34.9% market share in 2022, amassing US$ 588.34 million. It is projected to garner US$ 910.26 million by 2028 to expand at 7.5% CAGR during 2022–2028.

Based on country, the Asia Pacific influenza vaccines market has been categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 25.7% market share in 2022. It was assessed at US$ 434.65 million in 2022 and is likely to hit US$ 711.09 million by 2028, exhibiting a CAGR of 8.6% during the forecast period.

Key players dominating the Asia Pacific influenza vaccines market are AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd, among others.

  • In Mar,2020; Emergent BioSolutions Inc. announced an agreement with Novavax, Inc. whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavax’s NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant. Novavax recently announced that NanoFlu met all primary objectives in its Phase 3 clinical trial evaluating immunogenicity and safety in adults aged 65 and older.
  • In Jun,2022; Moderna, Inc. announced the first participants had been dosed in a Phase 3 study of the Company's seasonal influenza vaccine candidate (mRNA-1010). The trial is expected to enroll approximately 6,000 adults in Southern Hemisphere countries.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

Download Free PDF Brochure